

Amendments to the Specification:

Please delete line 29 on page 9 of the specification as filed.

BRIEF DESCRIPTION OF THE DRAWINGS

Please replace paragraph [0063] (starting on page 16, line 7) with the following amended paragraph:

-- Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. See, e.g., Batzer, et al. (1991) *Nucleic Acid Res.* 19:5081 [[-xxxx]]; Ohtsuka, et al. (1985) *J. Biol. Chem.* [[Chiem.]] 260:2605-2608; Rossolini, et al. (1994) *Mol. Cell. Probes* 8:91-98. The term nucleic acid is typically used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide. --

Please replace paragraph [0019] (page 4, line 20-23) with the following amended paragraph:

-- In various other embodiments, the pharmaceutical composition further includes a therapeutically compatible buffer or excipient, or includes a second therapeutic or anti-microbial agent. The second therapeutic agent may be, e.g., an inflammatory agent or an anti-inflammatory agent, or the second microbial agent can be, e.g., an antibiotic or a second anti-bacterial phage.--

Please replace paragraph [0133] (page 37, line 9) with the following amended paragraph:

-- With respect to aerosol administration to the lungs, the phage composition is typically incorporated into an aerosol formulation specifically designed for administration to the lungs by inhalation. Many such aerosols are known in the art, and the present invention is not limited to any particular formulation. An example of such an aerosol is the PROVENTIL® (albuterol)

Appl. No. 10/574,812

Amdt. dated March 22, 2011

Reply to Office Action of November 22, 2010

PATENT

~~Proventil-quadrature~~ inhaler manufactured by Schering-Plough, the propellant of which contains trichloromonofluoromethane, dichlorodifluoromethane, and oleic acid. The concentrations of the propellant ingredients and emulsifiers are adjusted if necessary based on the phage composition being used in the treatment. The number of phage to be administered per aerosol treatment will be typically in the range of 10^6 to 10^{13} ~~106 to 1013~~ killing units, and preferably 10^{12} ~~[[1012]]~~ killing units. ~~[KLB: this doesn't match the dose/kg indicated above]~~ --